Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia

• Status: Completed
• Trial end date: 2015-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Up to two hundred (200) adult participants with type 1 diabetes (T1D) aged 18 to 75 years will be selected for inclusion in the study. The target is to obtain treatment response and user-experience data following use of nasal glucagon (AMG504-1) in treating episodes of hypoglycemia. The population will be enriched to include participants who suffer from impaired hypoglycemia awareness.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company; Locemia Solutions ULC
• Collaborator: Locemia Solutions ULC
• Treatments: Glucagon; Glucagon-Like Peptide 1

Criteria

Inclusion Criteria:

• Male or Female Person with diabetes (PWD) lives with or is in frequent contact with one or more caregivers who are available to administer the glucagon in case of an episode of severe or moderate hypoglycemia

• With a history of type 1 diabetes >1 year

• At least 18 years of age but not older than 75 years

• Body mass index (BMI) greater than or equal to 18.50 and below 35.00 kg/m2.

• PWD will be otherwise healthy according to medical history, general physical examination (including vital signs), nasal examination, and laboratory tests (biochemistry, hematology, and urinalysis).

• For female subjects, a urine pregnancy test must be negative.

Exclusion Criteria:

• Presence or history of pheochromocytoma (i.e. adrenal gland tumor) or insulinoma.

• Use of a daily systemic beta-blockers, indomethacin, warfarin or anticholinergic drugs.